Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Dren Bio
Wake Forest University Health Sciences
AVM Biotechnology Inc
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Medical College of Wisconsin
AvenCell Therapeutics, Inc.
Vironexis Biotherapeutics Inc.
Karolinska University Hospital
Pfizer
Syndax Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Chicago
Ossium Health, Inc.
Zhejiang University
University of Miami
Children's Hospital Medical Center, Cincinnati
Institute of Hematology & Blood Diseases Hospital, China
Dana-Farber Cancer Institute
Stanford University
University of Colorado, Denver
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Indiana University
Memorial Sloan Kettering Cancer Center
Adela, Inc
AstraZeneca
Sheba Medical Center
Medical University of Gdansk
Zhongnan Hospital
AbbVie
First Ascent Biomedical Inc.
Thomas Helleday Foundation
Dana-Farber Cancer Institute
AbbVie
Goethe University
Hospital General de Mexico
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
University Health Network, Toronto
Fred Hutchinson Cancer Center
Kura Oncology, Inc.
M.D. Anderson Cancer Center
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
VA Office of Research and Development